CRISPR company Intellia prices IPO

Written by LVS on in the category news with the tags , , .

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) raised $108 million on Thursday through the sale of 6 million shares at $18 in an IPO underwritten by Credit Suisse, Jefferies, Leerink and Wedbush PacGrow. In a regulatory filing earlier Thursday, Intellia said it hoped to sell 5 million shares at $16-$18.

Intellia is one of a handful of companies developing products using CRISPR-Cas9 (CRISPR-associated protein 9) genome editing technology. The first to go public, Editas Medicine Inc. (NASDAQ:EDIT), closed at $31.99 on Thursday, up 100% from its Feb. 2 IPO price of $16.

Intellia expects its shares to begin trading on Friday.

Adapted from BioCentury.

Read more about: , , .

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent GSK Turnstone Itera Life Science XpandInnovation KU Leuven Janssen Biowin V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via or by completing the contact form.